Literature DB >> 15256494

Ghrelin degradation by serum and tissue homogenates: identification of the cleavage sites.

Carine De Vriese1, Francoise Gregoire, Roger Lema-Kisoka, Magali Waelbroeck, Patrick Robberecht, Christine Delporte.   

Abstract

The endogenous ligand for the GH secretagogue receptor is ghrelin, a peptide recently purified from the stomach. Ghrelin is n-octanoylated on the Ser(3) residue, and this modification is essential for its interaction with the receptor. The degradation of ghrelin by rat and human serum, purified commercial enzymes, and tissues homogenates was analyzed by combining HPLC and mass spectrometry. In serum, ghrelin was desoctanoylated, without proteolysis. The desoctanoylation was significantly reduced by phenylmethylsulfonyl fluoride, a serine proteases and esterases inhibitor. In rat serum, the carboxylesterase inhibitor bis-p-nitrophenyl-phosphate totally inhibited ghrelin desoctanoylation, and a correlation was found between ghrelin desoctanoylation and carboxylesterase activity. Moreover, purified carboxylesterase degraded ghrelin. Thus, carboxylesterase could be responsible for ghrelin desoctanoylation in that species. In human serum, ghrelin desoctanoylation was partially inhibited by eserine salicylate and sodium fluoride, two butyrylcholinesterase inhibitors, but not by bis-p-nitrophenyl-phosphate and EDTA. Purified butyrylcholinesterase was able to degrade ghrelin, and there was a correlation between the butyrylcholinesterase and ghrelin desoctanoylation activities in human sera. This suggested that several esterases, including butyrylcholinesterase, contributed to ghrelin desoctanoylation in human serum. In contact with tissues homogenates, ghrelin was degraded by both desoctanoylation and N-terminal proteolysis. We identified five cleavage sites in ghrelin between residues -Ser(2)-(acyl)Ser(3)- (stomach and liver), -(acyl?)Ser(3)-Phe(4)- (stomach, liver, and kidney), -Phe(4)-Leu(5)- (stomach and kidney), -Leu(5)-Ser(6)- and -Pro(7)-Glu(8)- (kidney). In all cases, the resulting fragments were biologically inactive.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15256494     DOI: 10.1210/en.2004-0569

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  85 in total

Review 1.  Bariatric surgery evolution from the malabsorptive to the hormonal era.

Authors:  Ehab Akkary
Journal:  Obes Surg       Date:  2012-05       Impact factor: 4.129

2.  Cysteine thioesters as myelin proteolipid protein analogues to examine the role of butyrylcholinesterase in myelin decompaction.

Authors:  Ian R Pottie; Emma A Higgins; Rachelle A Blackman; Ian R Macdonald; Earl Martin; Sultan Darvesh
Journal:  ACS Chem Neurosci       Date:  2010-12-30       Impact factor: 4.418

3.  Ghrelin-induced activation of cAMP signal transduction and its negative regulation by endocannabinoids in the hippocampus.

Authors:  Jacquelynn N Cuellar; Masako Isokawa
Journal:  Neuropharmacology       Date:  2010-12-25       Impact factor: 5.250

4.  Potential anti-obesity effects of a long-acting cocaine hydrolase.

Authors:  Xirong Zheng; Jing Deng; Ting Zhang; Jianzhuang Yao; Fang Zheng; Chang-Guo Zhan
Journal:  Chem Biol Interact       Date:  2016-05-06       Impact factor: 5.192

5.  Effects of glucose and insulin on acyl ghrelin and desacyl ghrelin, leptin, and adiponectin in pregnant women with diabetes.

Authors:  William Gibson; Jianhua Liu; Bruce Gaylinn; Michael O Thorner; Graydon S Meneilly; Sandra L Babich; David Thompson; Jean-Pierre Chanoine
Journal:  Metabolism       Date:  2009-12-16       Impact factor: 8.694

6.  Kinetics of human serum butyrylcholinesterase inhibition by a novel experimental Alzheimer therapeutic, dihydrobenzodioxepine cymserine.

Authors:  Mohammad A Kamal; Peter Klein; Weiming Luo; Yazhou Li; Harold W Holloway; David Tweedie; Nigel H Greig
Journal:  Neurochem Res       Date:  2007-11-06       Impact factor: 3.996

7.  Physiologic concentrations of exogenously infused ghrelin reduces insulin secretion without affecting insulin sensitivity in healthy humans.

Authors:  Jenny Tong; Ronald L Prigeon; Harold W Davis; Martin Bidlingmaier; Matthias H Tschöp; David D'Alessio
Journal:  J Clin Endocrinol Metab       Date:  2013-04-15       Impact factor: 5.958

Review 8.  Ghrelin forms in the modulation of energy balance and metabolism.

Authors:  Gianluca Gortan Cappellari; Rocco Barazzoni
Journal:  Eat Weight Disord       Date:  2018-10-24       Impact factor: 4.652

9.  Catalytic antibody degradation of ghrelin increases whole-body metabolic rate and reduces refeeding in fasting mice.

Authors:  Alexander V Mayorov; Neri Amara; Jason Y Chang; Jason A Moss; Mark S Hixon; Diana I Ruiz; Michael M Meijler; Eric P Zorrilla; Kim D Janda
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-03       Impact factor: 11.205

10.  Plasma butyrylcholinesterase regulates ghrelin to control aggression.

Authors:  Vicky Ping Chen; Yang Gao; Liyi Geng; Robin J Parks; Yuan-Ping Pang; Stephen Brimijoin
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-02       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.